Introduction

Tariffs on pharmaceutical imports are likely to increase drug prices for US patients because they raise input costs across highly globalized supply chains, reduce competitive pressure, and introduce inefficiencies that are typically passed through to consumers rather than absorbed by firms.

How tariffs increase drug prices for US patients

1. Globalized supply chains amplify cost pass-through

Pharmaceutical production is deeply integrated across borders, with active pharmaceutical ingredients (APIs), intermediates, and finished products often produced in different countries. Tariffs applied at any stage increase cumulative costs as inputs cross borders multiple times.

High regulatory and quality constraints limit firms’ ability to switch suppliers quickly, and because production is specialized and geographically concentrated, substitution is costly and slow. As a result, higher import costs are largely passed through the supply chain, raising final drug prices for patients rather than being absorbed through efficiency gains, underscoring the sensitivity of pharmaceutical supply chains to trade frictions.¹

2. Limited domestic substitution reduces competitive pressure

Tariffs are often intended to encourage domestic production, but in pharmaceuticals, this effect is constrained by structural factors. Manufacturing capacity — especially for APIs and complex biologics — requires long-term investment, regulatory approval, and specialized expertise.

In the short to medium term, tariffs do not significantly expand domestic supply. Instead, they reduce access to lower-cost foreign inputs and finished drugs, weakening price competition. This allows existing suppliers to maintain or increase prices without facing equivalent competitive pressure from imports.²

3. Tariffs function as a tax on essential goods

Tariffs act as a tax on imports, and in the case of pharmaceuticals, demand is relatively inelastic because medicines are essential goods. Patients and healthcare systems cannot easily reduce consumption in response to higher prices.

As a result, the burden of tariffs falls disproportionately on consumers, insurers, and public healthcare systems, rather than absorbed by producers or offset by efficiency gains.³

4. Regulatory and market structures reinforce price increases

Pharmaceutical markets are characterized by patent protections, regulatory barriers, and limited supplier competition for many products. These features already constrain price competition.

When tariffs are introduced, they interact with these structural features to reinforce upward price pressures. Firms facing higher import costs have limited incentives or ability to reduce margins, particularly for patented or specialized drugs where competition is limited.¹

Conclusion

Tariffs on pharmaceutical imports tend to increase drug prices because they raise costs within complex global supply chains, fail to generate rapid domestic substitution, and are passed through to consumers in a market with inelastic demand and limited competition. Rather than reducing prices or improving affordability, such measures risk increasing the financial burden on patients and healthcare systems while introducing inefficiencies into essential medical supply chains.